secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001193125-23-207397
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q2 net loss $35.5M; stops VGX-3100 cervical program, cuts 30% staff
--------------------------------------------------------------------------

- Net loss of $35.5M ($0.13 per share) on revenue of $226K; cash, equivalents & short-term investments $194.9M.
- Ceasing U.S. development of VGX-3100 for cervical HSIL after biomarker analysis; shifting focus to INO-3107 Phase 3 for RRP targeted for Q1 2024.
- Reducing workforce by 58 employees (30%) for ~$9.9M annual savings; cash runway extended into Q3 2025.
- R&D expenses fell to $23.7M from $56.5M; G&A dropped to $13.5M from $48.5M YoY, partly due to lower COVID-related costs and litigation settlement.
- ApolloBio continues VGX-3100 Phase 3 for cervical HSIL in China; INOVIO exploring anal HSIL and other pipeline candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/0001193125-23-207397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/d538749d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-207397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer